Institutes for Systems Genetics, West China Hospital
Copyright @ 2022 ISG. All Rights Reserved.
ncRNA
hsa-miR-302b-3p
Specific or universal ncRNAs
Specific ncRNAs
Class
MicroRNA
Biomarker
Yes
Biomarker application
Prognosis
Upstream regulatory factor
Not available
Downstream target
Not available
Differential expression in
recurrence vs. nonrecurrence
Not available
Cancer name
Bladder Cancer
Alias
Cancer site
Bladder
Recurrence type
Recurrence
Overall survival rate of patients with
high ncRNA expression
Down
ncRNA differential expression in
cancer
patients vs. health people
Not available
Number of patients
48
Male patients
41
Female patients
7
Age range and number
15(<60)+33(>=60)
Recurrence patients
Not available
Recurrence patients male:female
Not available
Recurrence patients age range
Not available
Recurrence mean age
Not available
Sites of recurrence
Not available
Patients without recurrence
Not available
Patients without recurrence male:female
Patients without recurrence age range
Not available
Patients without recurrence mean age
Not available
PMID
Description
The prognosis analysis demonstrated that the patients with low expression of miR-302b experienced high risks of recurrence.
Tissue resource
bladder cancer cell lines T24
bladder cancer cell lines 5637
bladder cancer cell lines UM-UC-3
bladder cancer cell lines J82
bladder cancer cell lines RT4
normal transitional epithelial cell SV-HUC-1
paired urothelial carcinoma and adjacent non-carcinoma bladder tissues
Experiment
qRT-PCR
Institute
Shanghai Institute of Biochemistry and Cell Biology
the Peking University Shenzhen Hospital
Country
China
Continent
Asia
Institutes for Systems Genetics, West China Hospital
Copyright @ 2022 ISG. All Rights Reserved.